Submitted by Anonymous (not verified) on 1 April 2025 - 15:18
Opinion/decision on a Paediatric investigation plan (PIP): Sarclisa, Isatuximab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0049/2024
Source: